Tsai Chen Lung 4
4 · CapsoVision, Inc · Filed Jul 7, 2025
Insider Transaction Report
Form 4
Tsai Chen Lung
Director
Transactions
- Conversion
Common Stock
2025-07-03+91,432→ 115,456 total(indirect: By Trust) - Conversion
Series D-1 Preferred Stock
2025-07-03−55,555→ 0 total(indirect: By Trust)→ Common Stock (16,683 underlying) - Conversion
Series E Preferred Stock
2025-07-03−86,956→ 0 total(indirect: By Trust)→ Common Stock (26,112 underlying) - Conversion
Series H Preferred Stock
2025-07-03−90,534→ 0 total(indirect: By Trust)→ Common Stock (27,187 underlying) - Conversion
Series B Preferred Stock
2025-07-03−71,429→ 0 total(indirect: By Trust)→ Common Stock (21,450 underlying)
Footnotes (2)
- [F1]Each share of Series B preferred stock, Series D-1 preferred stock, Series E preferred stock and Series H preferred stock automatically converted into approximately 0.3003 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split of the Issuer's common stock effected by the Issuer on July 2, 2025 in connection with its initial public offering.
- [F2]The securities are held by The Tsai Family Trust, for which the Reporting Person, together with his wife, are trustees.